Navigation Links
Nektar Therapeutics to Present at the UBS 2009 Global Life Sciences Conference in New York City
Date:9/18/2009

SAN CARLOS, Calif., Sept. 18 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) is scheduled to present at the upcoming UBS 2009 Global Life Sciences Conference in New York at the Grand Hyatt Hotel on Tuesday, September 22, 2009 at 10:30 a.m. Eastern time.

The presentation will be accessible via a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com. This Webcast will be available for replay until October 25, 2009.

About Nektar

Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug development expertise have enabled nine approved products in the U.S. or Europe for partners, which include leading biopharmaceutical companies, including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia. Nektar has created a robust pipeline of potentially high-value therapeutics to address unmet medical needs by leveraging and expanding its technology platforms to improve and enable molecules. Nektar is currently conducting clinical and preclinical programs in oncology, pain and other therapeutic areas. NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 clinical study in patients with refractory solid tumors.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

    Nektar Contacts:

    Jennifer Ruddock
    Nektar Therapeutics
    650-631-4954
    jruddock@nektar.com

    Susan Noonan
    The SAN Group
    212-966-3650
    susan@sanoonan.com


'/>"/>
SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
2. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
3. Nektar to Announce Financial Results for the First Quarter of 2009 on Wednesday, May 6, 2009, After Close of U.S.-Based Financial Markets
4. Nektar Therapeutics Repurchases $100 Million of Convertible Debt and Reports Third Quarter 2008 Financial Results
5. Nektar to Announce Financial Results for the Third Quarter of 2008 on Thursday, November 6, 2008 After Close of U.S.-Based Financial Markets
6. Nektar Therapeutics Announces Second Quarter 2008 Results
7. Nektar Therapeutics Names Randall Moreadith, M.D., Ph.D. Senior Vice President, Drug Development and Chief Development Officer
8. Nektar Therapeutics Announces First Quarter 2008 Results
9. FDA Approval of Cimzia(R) for Crohns Disease Represents Latest Milestone for Nektars PEGylation Technology Platform
10. Nektar Therapeutics Announces Fourth Quarter and Year-End 2007 Financial Results
11. Nektar to Announce 2007 Year-End Financial Results on Wednesday, February 27, 2008, After Close of U.S.-Based Financial Markets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 25, 2016 , ... Furthering its position as the industry leader in drug ... Free Sport (Drug Free Sport®) is excited to expand on details of its “Sport ... – 13 in Kansas City, MO, will gather sports industry professionals to examine, address ...
(Date:5/25/2016)... ... May 25, 2016 , ... According to an article published ... that would effectively fight against common bacteria and protect against surgical site infections. The ... hernia repair surgery even safer and could further reduce the risk of ...
(Date:5/25/2016)... ... ... The Bank of America Charitable Foundation has awarded a grant to the General ... employment and successful careers in healthcare. On Wednesday, May 4th, Rick Bridwell, Bank of ... Medisend, parent organization and home of the General Myers Veterans Program. , “The ...
(Date:5/25/2016)... ... May 25, 2016 , ... Dr. Travis Schwarz is an experienced dentist ... Road, O’Fallon, MO 63366. He serves patients of all ages with a full menu ... Schwarz’s success is reflected in the superior patient reviews that he has consistently earned ...
(Date:5/25/2016)... (PRWEB) , ... May 25, 2016 , ... Cheryl Bowker ... has to bestow: the Dick McKenna Good Hands Legacy Award. McKenna ran one of ... others which continues to inspire all those who knew him. The award named for ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016  Diana Russell suffers from ... organs from the inside out.  This disease has put ... on her children and grandchildren to leave her home.  ... Diana,s family cannot haul the wheelchair.  So if there ... car, and Diana is left to wait for the ...
(Date:5/24/2016)... 24, 2016 The innovator ... , s first dual therapy stent, introduces ... OrbusNeich, a global company specializing in the ... to include products to treat peripheral artery disease. The ... entry devices for lower limb and arteriovenous (AV) fistula ...
(Date:5/24/2016)... Een app die artsen over de hele ... behandelen, hun kennis kunnen delen en van elkaar kunnen ... revolutionaire MDLinking App, ontwikkeld door een internationale groep artsen ... en oncologisch chirurg dr. Gijs van Acker . ... dinsdag 24 mei officieel gepresenteerd op het Amsterdam Startup ...
Breaking Medicine Technology: